Click HERE to register for our upcoming FREE Q&A webinar on ketamine regulations and the future of therapeutic psychedelic medicines! In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that
Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Commonly found in tablet or crystal form, MDMA is a potent psychoactive drug with stimulant properties that produces experiences of empathy and sympathy. Both are currently prohibited in Australia, but will soon be available for therapeutic use. In so
Do you want to join us for a webcast about the future of psychedelics? If so, you won’t want to miss the Seminar Group’s upcoming, day-long psychedelics webcast, Legal and Regulatory Landscape for Psychedelics. The webcast will take place virtually on Wednesday, January 26, 2022, starting at 9:00 AM PST. Harris Bricken attorney Griffen Thorne
